Pharmaceutical company Eli Lilly today announced results of a phase III clinical trial that proves…
Kate O’NeillMay 3, 2023
Each year, the Down syndrome community and our supporters – family, friends, businesses, organizations and…
Kate O’NeillMarch 21, 2023
"Alzheimer's meds are here. But for the Down syndrome community, it's still the 1980s" by…
Kate O’NeillMarch 2, 2023
2/22/2023 (Burlington, MA) – Today the LuMind IDSC Foundation, a leading national Down syndrome research…
Kate O’NeillFebruary 23, 2023
The LuMind IDSC community and caregivers across the U.S. participated in “Challenges of Caregiving,” an…
Jo ZhouJanuary 26, 2023
Dear Friend of LuMind IDSC, Recently, I spoke with a family whose newborn baby had…
Jo ZhouJanuary 18, 2023
On Friday, January 6, the U.S. Food & Drug Administration (FDA) granted accelerated approval for…
Kate O’NeillJanuary 10, 2023
Our Impact Report 2022 highlights our accomplishments as an organization during a remarkable year. 2022 saw Down syndrome research receive unprecedented attention from policymakers, the media, and the pharmaceutical and life sciences industries. Click here to read our full report!
https://lumindidsc.org/wp-content/uploads/2023/01/Impact_Report_2022_FINAL_Digital.pdf
At an Alzheimer’s disease research conference last week, new clinical trial data was presented for…
Kate O’NeillDecember 5, 2022